Elkfork Partners’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Elkfork Partners’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$100K	Buy	+3,672	New	+$94.9K	﹤0.01%	948

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Elkfork Partners's HZNP Position: Q3 2019 in Review

Elkfork Partners opened a new position in Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2019: 3,672 shares worth $100K. The stake represents ﹤0.01% of the portfolio and ranks #948 among its holdings.

264 funds tracked by Wall St. Rank hold HZNP as of Q3 2019.

Elkfork Partners held 3,672 shares of Horizon Therapeutics Public Limited Company Ordinary Shares worth $100K as of Q3 2019.
Horizon Therapeutics Public Limited Company Ordinary Shares was a new Elkfork Partners position in Q3 2019.
Horizon Therapeutics Public Limited Company Ordinary Shares made up ﹤0.01% of Elkfork Partners's portfolio in Q3 2019, its #948 holding.
264 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2019.

Based on Elkfork Partners's 13F filing for Q3 2019, filed 14 Nov 2019.